|
A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302). |
|
|
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen |
Research Funding - AbGenomics International (Inst); Amgen (Inst); Amgen (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novocure (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst) |
Travel, Accommodations, Expenses - Abbvie; Halozyme |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Array BioPharma; Bayer; Foundation Medicine; Natera; Research to Practice; Research to Practice; Taiho Pharmaceutical |
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Incyte (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Nucana (Inst); Onyx (Inst); Pfizer (Inst); Pfizer/Calithera (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Array BioPharma |
|
|
Consulting or Advisory Role - Pierre Fabre |
|
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Nucana |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Nucana |
|
|
Consulting or Advisory Role - Abbvie; Bayer Health; Celgene; Clovis Oncology; Cornerstone Pharmaceuticals; EMD Serono; ipsen; qed therapeutics |
Research Funding - Abbvie (Inst); Bayer (Inst); boston biomedical (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); I-MAB (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); pfizer (Inst); Pharmacyclics (Inst); PsiOxus Therapeutics (Inst) |
Travel, Accommodations, Expenses - Bayer; boston Biomedical; EMD Serono |
Other Relationship - novocure; Pancreatic Cancer Action Network |
|
|
Stock and Other Ownership Interests - RNA Guardian; RNA Guardian (I) |
Speakers' Bureau - Clovis Oncology; Octimet |
Research Funding - Incyte; Nucana; Octimet; Piqur; Redx Pharma; Sierra Pharma; Tesaro |
Patents, Royalties, Other Intellectual Property - WO 2016075455 A1 circulating LARP1 |
Travel, Accommodations, Expenses - Nucana; Tesaro |
|
|
Honoraria - Ascelia (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst) |
Consulting or Advisory Role - Karus Therapeutics (Inst) |
Speakers' Bureau - Bristol-Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); United Medical (Inst) |
Research Funding - Adaptimmune (Inst); AstraZeneca (Inst); Athenex (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOncologi (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sierra Pharma (Inst); Starpharma (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst) |
Expert Testimony - Medivir (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre |
Other Relationship - Genmab (Inst) |